We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
 Irvine Introduces Chemically-Defined Dendritic Cell Culture Medium for Immunotherapy Applications
Product News

Irvine Introduces Chemically-Defined Dendritic Cell Culture Medium for Immunotherapy Applications

 Irvine Introduces Chemically-Defined Dendritic Cell Culture Medium for Immunotherapy Applications
Product News

Irvine Introduces Chemically-Defined Dendritic Cell Culture Medium for Immunotherapy Applications

Image Credit: Irvine Scientific

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of " Irvine Introduces Chemically-Defined Dendritic Cell Culture Medium for Immunotherapy Applications"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Irvine Scientific,  announced the introduction of PRIME-XV Dendritic Cell Maturation CDM, a chemically-defined, animal component-free medium for the differentiation of monocytes into immature dendritic cells, and subsequent maturation in dendritic cells.

Current approaches to immunotherapy include harnessing the power of the body’s immune system to treat tumors with cell therapies.  One approach is through vaccination, a method where an antigen together with an adjuvant stimulates the body to create therapeutic T cells. Dendritic cells (DCs) are the most potent antigen-presenting cells capable of priming naïve T cells and are therefore essential tools in the activation of immune responses to tumors. They can be generated in vitro from CD14+ peripheral blood or cord blood monocytes through a maturation process. It is essential for these monocyte-derived DCs (Mo-DCs) to maintain their functional capacity of the launching antigen-specific immunity, leading to T cell activation into therapeutic T cells. Serum and undefined components found in animal- or human-derived raw materials can negatively affect this Mo-DC functional capacity. PRIME-XV Dendritic Cell Maturation CDM provides a robust method for the generation of Mo-DCs in chemically-defined culture conditions, thereby maintaining their capacity to induce T cell response.


“Our continuous research on the effects of components in media has produced convincing data that culturing cells in chemically-defined conditions improves the ability to reliably produce populations of cells that maintain desired functionality and morphology compared to culture media containing animal-derived components.” said Jessie H.-T. Ni, Chief Scientific Officer, Irvine Scientific. “Chemically-defined media also reduces the risk of introducing foreign agents or impurities from undefined components, thereby facilitating scale-up to commercial production and the regulatory submission process.”


PRIME-XV Dendritic Cell Maturation CDM is the ideal complement to PRIME-XV T Cell CDM, the first commercially available chemically-defined medium for T cell culture. Together they provide a complete workflow free from the variability and risk of contamination that the use of animal-derived components presents. All products are manufactured using stringent raw material qualification and under Current Good Manufacturing Practices (cGMP) for consistency and reliability.


Advertisement